ATE347906T1 - Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen - Google Patents

Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Info

Publication number: ATE347906T1
Authority: AT; Austria
Prior art keywords: ultrafiltration; ammonium sulfate; polysaccharide; purification; protein conjugate
Prior art date: 1998-12-29

Application number

AT99967388T

Other languages

English (en)

Inventor

Ronald P Mcmaster

Original Assignee

Connaught Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-29

Filing date

1999-12-16

Publication date

2007-01-15

1999-12-16 Application filed by Connaught Lab filed Critical Connaught Lab

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE347906T1 publication Critical patent/ATE347906T1/de

Links

BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 title abstract 2
229910052921 ammonium sulfate Inorganic materials 0.000 title abstract 2
235000011130 ammonium sulphate Nutrition 0.000 title abstract 2
238000000108 ultra-filtration Methods 0.000 title abstract 2
108010060123 Conjugate Vaccines Proteins 0.000 title 1
229940031670 conjugate vaccine Drugs 0.000 title 1
238000000746 purification Methods 0.000 title 1
239000012471 diafiltration solution Substances 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
229940023143 protein vaccine Drugs 0.000 abstract 1
238000009738 saturating Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT99967388T 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen ATE347906T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/221,728 US6146902A (en)	1998-12-29	1998-12-29	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions

Publications (1)

Publication Number	Publication Date
ATE347906T1 true ATE347906T1 (de)	2007-01-15

Family

ID=22829099

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99967388T ATE347906T1 (de)	1998-12-29	1999-12-16	Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
AT06025470T ATE496633T1 (de)	1998-12-29	1999-12-16	Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT06025470T ATE496633T1 (de)	1998-12-29	1999-12-16	Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Country Status (11)

Country	Link
US (1)	US6146902A (de)
EP (3)	EP2292261A1 (de)
AT (2)	ATE347906T1 (de)
AU (1)	AU2367500A (de)
CA (2)	CA2621097A1 (de)
CY (3)	CY1105985T1 (de)
DE (3)	DE06025470T1 (de)
DK (2)	DK1140156T3 (de)
ES (2)	ES2277462T3 (de)
PT (2)	PT1762245E (de)
WO (1)	WO2000038711A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6248334B1 (en) *	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
CZ20024224A3 (cs) *	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
MXPA03003396A (es) *	2000-10-18	2004-12-13	Clarity Technologies Inc	Metodo y dispositivo para diluir un fluido y detectar analitos dentro de un fluido diluido.
SI21352A (sl) *	2001-01-23	2004-06-30	Aventis Pasteur	Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
JP2004534527A (ja)	2001-04-04	2004-11-18	デーエスエムイーペーアセッツベスローテンフェンノートシャップ	精製ラクターゼ
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
EP2172213B1 (de)	2003-01-30	2013-04-03	Novartis AG	Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
CN1852733A (zh)	2003-05-07	2006-10-25	安万特巴斯德公司	多价脑膜炎球菌衍生的多糖－蛋白质缀合物及疫苗
BRPI0410423A (pt)	2003-05-07	2006-06-06	Sanofi Pasteur Inc	processo de imunogenicidade melhorada para vacinação meningocócica
JP2007516181A (ja)	2003-06-23	2007-06-21	アヴェンティスパストゥールインコーポレイテッド	髄膜炎菌血清群ａおよびｃに対する免疫方法
CA2530364C (en) *	2003-06-23	2014-03-18	Baxter International Inc.	Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
CA2556169C (en) *	2004-01-29	2011-11-22	Andrew Lees	Use of amino-oxy functional groups in the preparation of vaccines
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
KR20070101207A (ko) *	2004-08-30	2007-10-16	사노피 파스퇴르 인크	다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
MX2007003292A (es) *	2004-09-21	2007-09-07	Sanofi Pasteur Inc	Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes.
GB0502096D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
PE20110072A1 (es) *	2005-06-27	2011-02-04	Glaxosmithkline Biolog Sa	Composicion inmunogenica
GB0513852D0 (en) *	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en) *	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) *	2006-03-22	2006-05-03	Chiron Srl	Separation of conjugated and unconjugated components
PL2004225T3 (pl) *	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
CN101663327B (zh)	2007-03-23	2014-05-07	惠氏公司	产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2777837C (en)	2008-10-27	2017-07-11	Novartis Ag	Purification method
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
ES2749952T3 (es)	2008-12-18	2020-03-24	Wyeth Llc	Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
BRPI0922981A8 (pt) *	2008-12-18	2019-11-26	Wyeth Llc	método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
SA110310528B1 (ar)	2009-06-22	2014-07-02	Wyeth Llc	التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en)	2009-06-22	2014-11-27	Wyeth Llc	Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011017101A2 (en) *	2009-07-27	2011-02-10	Fina Biosolutions, Llc	Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
BR112012009014B8 (pt)	2009-09-30	2022-10-04	Novartis Ag	Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
HUE034251T2 (en)	2009-10-30	2018-02-28	Glaxosmithkline Biologicals Sa	Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
US8105843B2 (en) *	2009-11-04	2012-01-31	Buchanan Thomas M	Methods and devices to enhance sensitivity and evaluate sample adequacy and reagent reactivity in rapid lateral flow immunoassays
CA2836153C (en)	2009-12-17	2016-06-21	Fina Biosolutions, Llc	Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
WO2011080595A2 (en)	2009-12-30	2011-07-07	Novartis Ag	Polysaccharide immunogens conjugated to e. coli carrier proteins
EP2560738B8 (de)	2010-04-23	2019-09-25	Serum Institute of India Private Limited	Einfaches verfahren zur simultanen beseitigung mehrerer unreinheiten aus kulturüberständen auf extrem geringe konzentrationen
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
CA2860331A1 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
US9358284B2 (en)	2011-09-14	2016-06-07	Glaxosmithkline Biologicals Sa	Methods for making saccharide-protein glycoconjugates
WO2013049535A2 (en)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Influenza vaccine
RU2636350C2 (ru)	2011-11-07	2017-11-22	Новартис Аг	МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
RU2014151567A (ru)	2012-05-22	2016-07-10	Новартис Аг	Конъюгат менингококка серогруппы х
TR201808684T4 (tr)	2012-10-02	2018-07-23	Glaxosmithkline Biologicals Sa	Lineer olmayan sakarit konjügatları.
RU2015106791A (ru)	2012-10-03	2016-11-20	Глэксосмитиклайн Байолоджикалз Са	Иммуногенные композиции
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN104387491B (zh) *	2014-11-25	2017-12-05	中国医学科学院医学生物学研究所	一种b型流感嗜血杆菌荚膜多糖的制备方法
BE1024634B1 (fr)	2016-04-05	2018-05-14	Gsk Vaccines S.R.L.	Compositions immunogenes
BR112019003992A2 (pt)	2016-09-02	2019-05-28	Sanofi Pasteur Inc	vacina contra neisseria meningitidis
WO2018067582A2 (en)	2016-10-03	2018-04-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en)	2016-10-31	2021-12-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Peptide fragments from filoviruses and their uses
BE1025162B9 (fr)	2016-12-06	2019-01-07	Glaxosmithkline Biologicals Sa	Procede de purification pour les polysaccharides capsulaires
EP4656208A3 (de)	2017-01-31	2026-03-04	Merck Sharp & Dohme LLC	Verfahren zur herstellung von polysaccharid-protein-konjugaten
CN110225757A (zh) *	2017-01-31	2019-09-10	默沙东公司	由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
MX2019009869A (es)	2017-02-24	2019-10-02	Merck Sharp & Dohme	Formulaciones de vacunas de conjugado de neumococos.
CN111093650B (zh)	2017-09-07	2024-03-01	默沙东有限责任公司	肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
ES3058336T3 (es)	2017-12-06	2026-03-10	Merck Sharp & Dohme Llc	Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
US12144855B2 (en)	2018-04-30	2024-11-19	Merck Sharp & Dohme Llc	Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
EP3788143B1 (de)	2018-04-30	2023-06-28	Merck Sharp & Dohme LLC	Verfahren zur bereitstellung einer homogenen lösung eines lyophilisierten mutierten diphtherietoxins in dimethylsulfoxid
EP3787673A4 (de)	2018-04-30	2022-04-27	Merck Sharp & Dohme Corp.	Verfahren zur herstellung von kapsulären streptococcus-pneumoniae-polysaccharid-trägerproteinkonjugaten
US12053519B2 (en)	2018-09-23	2024-08-06	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
CR20210333A (es)	2018-12-19	2021-08-18	Merck Sharp & Dohme	Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
BR112021022429A2 (pt)	2019-05-10	2022-03-22	Glaxosmithkline Biologicals Sa	Produção de conjugados
MX2022015860A (es)	2020-06-12	2023-01-24	Glaxosmithkline Biologicals Sa	Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas.
MX2023005517A (es)	2020-11-13	2023-08-21	Glaxosmithkline Biologicals Sa	Novedosos portadores y métodos de conjugación.
TW202245835A (zh)	2021-02-04	2022-12-01	美商默沙東有限責任公司	用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US20240101597A1 (en) *	2021-02-26	2024-03-28	The Penn State Research Foundation	Separation apparatus and method
WO2023111826A1 (en)	2021-12-14	2023-06-22	Glaxosmithkline Biologicals Sa	Bacterial immunization using qbeta hairpin nanoparticle constructs
AU2023254751A1 (en)	2022-04-11	2024-11-21	Sanofi Pasteur Inc.	Protein-saccharide conjugation with sodium cyanoborohydride
CN121532194A (zh)	2023-05-18	2026-02-13	默沙东有限责任公司	用于肺炎球菌疫苗的化合物及佐剂制剂
WO2025106603A1 (en)	2023-11-16	2025-05-22	Merck Sharp & Dohme Llc	Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025174398A1 (en)	2024-02-14	2025-08-21	Merck Sharp & Dohme Llc	26-valent pneumococcal conjugate vaccines and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4459286A (en) *	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
US4456691A (en) *	1983-02-28	1984-06-26	Suad Stark	Antigen for PCB, antibody raised by same, and method of making same
NZ214503A (en) *	1984-12-20	1990-02-26	Merck & Co Inc	Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4780409A (en) *	1985-05-02	1988-10-25	Genetic Systems Corporation	Thermally induced phase separation immunoassay
JPH0643336B2 (ja) *	1988-06-30	1994-06-08	呉羽化学工業株式会社	血管増殖抑制剤
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) *	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
CA2059692C (en) *	1991-01-28	2004-11-16	Peter J. Kniskern	Pneumoccoccal polysaccharide conjugate vaccine
AU1140495A (en) *	1994-01-27	1995-08-03	Bristol-Myers Squibb Company	Method for preparing thioether conjugates
SE9601158D0 (sv) *	1996-03-26	1996-03-26	Stefan Svenson	Method of producing immunogenic products and vaccines
FR2748476B1 (fr) *	1996-05-07	1998-08-14	Pf Medicament	Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) *	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US5965714A (en) *	1997-10-02	1999-10-12	Connaught Laboratories, Inc.	Method for the covalent attachment of polysaccharides to protein molecules

1998
- 1998-12-29 US US09/221,728 patent/US6146902A/en not_active Expired - Lifetime
1999
- 1999-12-16 DE DE06025470T patent/DE06025470T1/de active Pending
- 1999-12-16 DK DK99967388T patent/DK1140156T3/da active
- 1999-12-16 AT AT99967388T patent/ATE347906T1/de active
- 1999-12-16 DK DK06025470.3T patent/DK1762245T3/da active
- 1999-12-16 ES ES99967388T patent/ES2277462T3/es not_active Expired - Lifetime
- 1999-12-16 ES ES06025470T patent/ES2278551T3/es not_active Expired - Lifetime
- 1999-12-16 CA CA002621097A patent/CA2621097A1/en not_active Abandoned
- 1999-12-16 AU AU23675/00A patent/AU2367500A/en not_active Abandoned
- 1999-12-16 EP EP10185779A patent/EP2292261A1/de not_active Withdrawn
- 1999-12-16 CA CA002358022A patent/CA2358022C/en not_active Expired - Lifetime
- 1999-12-16 EP EP06025470A patent/EP1762245B1/de not_active Expired - Lifetime
- 1999-12-16 AT AT06025470T patent/ATE496633T1/de active
- 1999-12-16 DE DE69934434T patent/DE69934434T2/de not_active Expired - Lifetime
- 1999-12-16 PT PT06025470T patent/PT1762245E/pt unknown
- 1999-12-16 EP EP99967388A patent/EP1140156B1/de not_active Expired - Lifetime
- 1999-12-16 DE DE69943169T patent/DE69943169D1/de not_active Expired - Lifetime
- 1999-12-16 PT PT99967388T patent/PT1140156E/pt unknown
- 1999-12-16 WO PCT/US1999/030109 patent/WO2000038711A2/en not_active Ceased
2007
- 2007-01-31 CY CY20071100130T patent/CY1105985T1/el unknown
- 2007-08-23 CY CY20072200004T patent/CY2200152T2/el unknown
2011
- 2011-04-05 CY CY20111100357T patent/CY1111375T1/el unknown

Also Published As

Publication number	Publication date
HK1106999A1 (en)	2008-03-28
CY2200152T2 (el)	2010-07-28
WO2000038711A2 (en)	2000-07-06
WO2000038711A3 (en)	2000-10-19
CA2621097A1 (en)	2000-07-06
EP1762245A2 (de)	2007-03-14
DE69934434D1 (de)	2007-01-25
CA2358022A1 (en)	2000-07-06
EP1762245B1 (de)	2011-01-26
ES2277462T3 (es)	2007-07-01
CY1111375T1 (el)	2015-08-05
ES2278551T3 (es)	2011-04-11
AU2367500A (en)	2000-07-31
CA2358022C (en)	2008-03-11
DK1762245T3 (da)	2011-04-04
EP2292261A1 (de)	2011-03-09
PT1140156E (pt)	2007-02-28
EP1140156A2 (de)	2001-10-10
DE69934434T2 (de)	2008-01-03
DE69943169D1 (de)	2011-03-10
ES2278551T1 (es)	2007-08-16
EP1140156B1 (de)	2006-12-13
US6146902A (en)	2000-11-14
DE06025470T1 (de)	2007-08-02
DK1140156T3 (da)	2007-03-26
ATE496633T1 (de)	2011-02-15
PT1762245E (pt)	2011-05-02
EP1762245A3 (de)	2007-04-25
CY1105985T1 (el)	2011-04-06

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1140156

Country of ref document: EP

Publication	Publication Date	Title
ATE496633T1 (de)	2011-02-15	Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
TR200200205T2 (tr)	2002-06-21	MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DE59100581D1 (de)	1993-12-16	Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
DE69603240D1 (de)	1999-08-19	Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
PT778771E (pt)	2005-08-31	Emulsoes topicas de cetoconazole
ATE153332T1 (de)	1997-06-15	Verfahren zur herstellung von oxetanonen
WO2003015694A3 (en)	2004-07-15	Agents for enhancing the immune response
IS4265A (is)	1995-08-19	Afleiður af mycophenolicsýrum, sem hafa efnahópa tengda-N-atómi í stöðu 6
DK0528494T3 (da)	1995-07-17	Katalysatorsammensætninger omfattende en modificeret zeolit af Y-typen
DE69625354D1 (de)	2003-01-23	Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
DK1283845T3 (da)	2004-04-13	Fremgangsmåde til fremstilling af farmaceutiske acceptable salte af (SS-RS)-S-adenosyl-L-methionin
DE69609054D1 (de)	2000-08-03	Ein prozess für die herstellung von faktor ix biologischen ursprungs
ATE517617T1 (de)	2011-08-15	Behandlung von parkinson erkrankung mit kape
DE69520947D1 (de)	2001-06-21	Diarinopropanole abgeleitet von aminosäuren
BR0016668A (pt)	2002-10-08	Processo para a preparação de n-fosfonometilglicina, processo para a preparação de um composto fosfono, composto fosfono, e, intermediário
ATE238791T1 (de)	2003-05-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
DE59104649D1 (de)	1995-03-30	Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
DE50103009D1 (de)	2004-09-02	Verfahren zur herstellung von 2-alkyl-3-chlorphenolen
DE59801815D1 (de)	2001-11-22	Verfahren zur herstellung von 1,2-dichlorethan durch oxichlorierung
ATE213734T1 (de)	2002-03-15	Verfahren zur herstellung von 1,3- disubstituierten 2-nitroguanidinen
BR0007960A (pt)	2001-11-06	Tablete detergente revestido
EA199900174A1 (ru)	1999-08-26	Способ лечения биполярного расстройства
DK0653482T3 (da)	2000-06-05	Hypochloritblegesammensætninger
DK0892810T3 (da)	2006-03-27	Krystallisation af et protein med et svovlsalt
DE60001225D1 (de)	2003-02-20	Verfahren zur herstellung von epipodophyllotoxine-4'-demethyl-4'-phosphat-2",3"-bis pentafluorphenoxyacetyl-4",6"-ethyliden- beta-d-glucosid und seine salzen